title: [Metastatic hormone-sensitive prostate cancer].
abstract: The prostate cancer in its hormone-sensitive metastatic presentation is infrequent, it is either an initial presentation of the disease or an evolution after local treatment, without castration of the biological relapse. The surgical or biological castration remains the cornerstone of the treatment. The deadline of castration initiation and its modalities of administration, intermittent or continuous rest debated but consensual on the initiation is the appearance of the symptomatic disease. The chemotherapy by docetaxel in association with the castration increases significantly the survival of the patients having a high tumoral volume. The efficacy on the whole metastatic population requires additional analyses. Clinical prognostic factors as the bone localizations (axial or appendicular), the visceral involvement (liver, lung) are determining for the survival of these patients. Biological prognostic factors are in evaluation. Except the clodronate acid, which showed a survival improvement in the hormone-sensitive metastatic prostate cancer (HSMPC), the other treatments targeting the bone (zoledronic acid, rank-ligand inhibitor) demonstrated a benefit only in castrate resistant metastatic prostate cancer (MCRPC). The management of local disease lets suggest a benefit to at least symptomatic disease, but it requires to be estimated prospectively in clinical trials. The new hormonal treatments targeting the androgen receptor in CPMRC are in evaluation in CPMHS. The objective is to increase the survival and the quality of life of the CPMHS and to delay the evolution towards the castration resistant metastatic disease.
authors.affiliation: Institut Paoli-Calmettes, oncologie médicale, centre de recherche en cancérologie de Marseille, UMR1068 Inserm, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France. Electronic address: gravisg@ipc.unicancer.fr.
authors.forename: Gwenaelle
authors.initials: G
authors.lastname: Gravis
authors.affiliation: Institut Paoli-Calmettes, service de radiothérapie, 13009 Marseille, France.
authors.forename: Naji
authors.initials: N
authors.lastname: Salem
authors.affiliation: Institut Paoli-Calmettes, service de chirurgie urologique, 13009 Marseille, France.
authors.forename: Jochen
authors.initials: J
authors.lastname: Walz
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D004002:Clodronic Acid / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D043823:Taxoids; D004002:Clodronic Acid; D000077143:Docetaxel
keywords: Cancer de la prostate; Cancer de la prostate métastatique; Castration-sensitive; Docetaxel; Docétaxel; Hormonosensible; M1; Metastatic prostate cancer; Non-castrate; Prostate cancer; Sensible à la castration